Trillium Therapeutics Inc. announced the closing of its previously announced transaction with Pfizer Inc. and PF Argentum Acquisition ULC pursuant to the previously announced arrangement agreement dated August 20, 2021, by and among Trillium, Pfizer and Purchaser. In connection with the completion of the Arrangement and following the Effective Time, Jan Skvarka, Chief Executive Officer ceased to serve in his capacity as executive officers of the company.